J1413Drugs Administered Other than Oral Method

Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose

Short description: Inj delandistrogene mox rokl

Effective date: January 1, 2024
Termination date: —

Related codes (J-series)

J0013Esketamine, nasal spray J0014Cocaine hcl nasal (goprelto)J0120Tetracyclin injection J0121Inj., omadacycline, 1 mg J0122Inj., eravacycline, 1 mg J0129Abatacept injection J0130Abciximab injection J0131Inj, acetaminophen (nos)J0132Acetylcysteine injection J0133Acyclovir injection J0134Inj acetaminophen -fresenius J0135Adalimumab injection

Frequently asked questions

What is HCPCS code J1413?

J1413 is a HCPCS Level II code for Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose.

What category is HCPCS code J1413 in?

J1413 falls under the Drugs Administered Other than Oral Method category of HCPCS Level II.

When did HCPCS code J1413 become effective?

J1413 has been effective since January 1, 2024, per CMS's quarterly HCPCS update.

HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.